NewslettersPulmonary Cell News First-Line Osimertinib for Previously Untreated Patients with NSCLC and Uncommon EGFR Mutations By Laurisa Dohm - November 27, 2023 0 The Phase II nonrandomized clinical trial enrolled 42 patients with uncommon EGFR mutations, of whom 40 were eligible. [Jama Oncology] Abstract